Truist Securities Initiates Coverage On Taysha Gene Therapies with Buy Rating, Announces Price Target of $60
Truist Securities analyst Joon Lee initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Buy rating and announces Price Target of $60.
BTIG Initiates Coverage On Taysha Gene Therapies with Buy Rating, Announces Price Target of $44
BTIG analyst Yun Zhong initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Buy rating and announces Price Target of $44.
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 10)
Earnings Scheduled For May 11, 2021
Companies Reporting Before The Bell
• Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter.
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure following the U.S.